JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | M. El-Mahdy El-Sayyad, Nihal | |
| dc.contributor.author | Badawi, Alia | |
| dc.contributor.author | Effat Abdullah, Mohammed | |
| dc.contributor.author | Shawky Abdelmalak, Nevine | |
| dc.date.accessioned | 2019-10-31T06:59:50Z | |
| dc.date.available | 2019-10-31T06:59:50Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | I.R. Ibrahim, M.I.M. Ibrahim, M.S.D. Al-Haddad The influence of consumers’ preferences and perceptions of oral solid dosage forms on their treatment Int. J. Clin. Pharm., 34 (5) (2012), pp. 32-72 View Record in ScopusGoogle Scholar [2] M.A. Alam, F.I. Al-Jenoobi, A.M. Al-mohizea Commercially bioavailable proprietary technologies and their marketed products Drug Discov. Today, 18 (19–20) (2013), pp. 936-949 ArticleDownload PDFView Record in ScopusGoogle Scholar [3] R. Lobenberg, G.L. Amidon Modern bioavailability, bioequivalence and biopharmaceutics classification system. New approaches to international regulatory standards Eur. J. Pharm. Biopharm., 50 (1) (2000), pp. 3-12 ArticleDownload PDFView Record in ScopusGoogle Scholar [4] M.J. Habib Pharmaceutical Solid Dispersion Technology Technomic publication company Inc, Lancaster, USA (2000) Google Scholar [5] J. Cook, W. Addicks, Y.H. Wu Application of the biopharmaceutical classification system in clinical drug development–an industrial view AAPS J., 10 (2) (2008), pp. 306-310 CrossRefView Record in ScopusGoogle Scholar [6] S. Spireas, Liquisolid systems and methods for preparing same, United States Patent US6423339 B1, 2000. Google Scholar [7] S. Spireas, S.M. Bolton, Liquisolid systems and methods of preparing same, United States Patent US5800834 A, 1998. Google Scholar [8] M. El-Hammadi, N. Awad Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release AAPS PharmSciTech, 13 (1) (2012), pp. 53-58 CrossRefView Record in ScopusGoogle Scholar [9] B. Akinlade, A. Elkordy, E. Essa, S. Elhaggar Liquisolid systems to improve the dissolution of furosemide Scientia Pharmacuetica, 78 (2010), pp. 325-344 CrossRefView Record in ScopusGoogle Scholar [10] Y. Javadzadeh, B. Jafari-Navimipour, A. Nokhodchi Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine) Int. J. Pharm., 341 (1–2) (2007), pp. 26-34 ArticleDownload PDFView Record in ScopusGoogle Scholar [11] K.A. Khaled, Y.A. Asiri, Y.M. El-Sayed In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs Int. J. Pharm., 222 (1) (2001), pp. 1-6 ArticleDownload PDFView Record in ScopusGoogle Scholar [12] R. Fahmy, M. Kassem Enhancement of famotidine dissolution rate through liquisolid tablet formulation: in vitro and In vivo evaluation Eur. J. Pharm. Biopharm., 69 (3) (2008), pp. 993-1003 ArticleDownload PDFView Record in ScopusGoogle Scholar [13] C.W. Pouton, C.J.H. Porter Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies Adv. Drug Deliv. Rev., 60 (6) (2008), pp. 625-637 ArticleDownload PDFView Record in ScopusGoogle Scholar [14] A.C. Koånik, M.G. Sznitowksa Solubility of ocular therapeutic agents in self emulsifying oils I. Self emulsifying oils for ocular drug delivery: solubility of Indomethacin Acta Pol. Pharm., 66 (6) (2009), pp. 709-713 Google Scholar [15] S. Gupta, R. Kesarla, A. Omri Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems ISRN Pharm. (2013), 10.1155/2013/848043 Google Scholar [16] B. Tang, G. Cheng, J.C. Gu, C.H. Xu Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms Drug Discov. Today (2008), pp. 606-612 ArticleDownload PDFView Record in ScopusGoogle Scholar [17] S. Sweetman Martindale: the complete drug reference. Electronic Version Pharmaceutical Press, London (2013) Google Scholar [18] D. Vega, A. Petragalli, D. Fernandez, J.A. Ellena Polymorphism on leflunomide: stability and crystal structures J. Pharm. Sci., 95 (5) (2006), pp. 1075-1083 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar [19] The United States pharmacopeia 36/National Formulary 31 Rockville, USA (2012) Google Scholar [20] ICH harmonized triparitate guideline: validation of analytical procedures: text and methodology Q2(R1), in: International Confrence on Harmonization of technical requirements for registration of pharmacueticals for human use, 2005. Google Scholar [21] Y. Javadzadeh, M.R. Siahi, S. Asnashaari, A. Nokhodshi Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties Acta Pharm., 57 (1) (2007), pp. 99-109 CrossRefView Record in ScopusGoogle Scholar [22] R.C. Rowe, P.J. Sheskey, S.C. Owen Handbook of Pharmaceutical Excipients (fifth ed.), Pharmaceutical press, London (2006) Google Scholar [23] A.K. Meena, K. Sharma, M. Kandaswamy, S. Rajagopal, R. Mullangi Formulation and in-vitro characterization of self nano emulsifying drug delivery system of cinnarizine Acta Pharm., 62 (4) (2012), pp. 563-580 View Record in ScopusGoogle Scholar [24] Y. Javadzadeh, H. Shariati, E. Movahhed-Danesh, A. Nokhodchi Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts Drug Dev. Ind. Pharm., 35 (2) (2009), pp. 243-251 CrossRefView Record in ScopusGoogle Scholar [25] ICH harmonized triparitate guideline, stability testing of new drug substances and products Q1A (R2), in: International Confrence on Harmonization of technical requirements for registration of pharmacueticals for human use, 2003. Google Scholar [26] World Health Organization (WHO), Annex 2: Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, WHO Technical Report Series, No. 953, 2009. Google Scholar [27] G.E. Amidon, P.J. Secreast, D. Mudie Particle, powder, and compact characterization Y. Qui, Y. Chen, G. Zhang (Eds.), Developing Solid Oral Dosage Forms Pharmaceutical Theory and Practice, Academic press, MA, USA (2009), pp. 163-183 View Record in ScopusGoogle Scholar [28] Y. Chen, C. Chen, J. Zheng, Z. Chen, Q. Shi, H. Liu Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability Biol. Pharm. Bull., 34 (2) (2011), pp. 278-286 CrossRefView Record in ScopusGoogle Scholar [29] J.A. McCauley, H.G. Brittain Thermal method of analysis H.G. Brittain (Ed.), Physical Characterization of Pharmaceutical Solids, Drugs and Pharmaceutical Sciences, Marcel Dekker Inc, New York (2005), pp. 223-250 CrossRefView Record in ScopusGoogle Scholar [30] P. Mura, M.T. Fauci, P.L. Parrini Effect of grinding with microcrystalline cellulose and cyclodextrins on the ketoprofen physicochemical properties Drug Deliv. Ind. Pharm., 27 (2) (2011), pp. 119-128 Google Scholar [31] B. Chen, Z. Wang, G. Quan, X. Peng, X. Pan, R. Wang, et al. In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation Int. J. Nanomed., 7 (2012), pp. 199-209 View Record in ScopusGoogle Scholar [32] S.K. Niazi Handbook of Preformulation: Chemical, Biological and Botanical Drugs Informa Heathcare, USA (2007) Google Scholar | en_US |
| dc.identifier.other | https://doi.org/10.1016/j.bfopcu.2017.02.001 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1110093117300066 | |
| dc.description.abstract | The objective of this study is to enhance the dissolution properties of leflunomide, a class BCS-II drug by incorporating the self emulsifying (SE) form of the drug onto liquisolid systems in the form of tablets. Different formulae were prepared by dissolving leflunomide in PEG300 then forming SE systems using tween 80 as surfactant and either sesame oil and paraffin oil then adsorbing on powder excipients to form SE liquisolid powders. The prepared powders showed adequate flowability. The drug and excipients showed compatibility by analysis with DSC, XRD and FTIR. After compression, all tablets showed adequate weight variation, friability and disintegration time with disintegration time ranging between 8.45 ± 0.16 min and 10.7 ± 0.29 min. All liquisolid tablets exhibited higher in vitro dissolution in distilled water compared to physical mixture and the commercial tablets (Arthfree®) with formula containing sesame oil and highest amount of solvent (TS04) exhibiting the highest dissolution profile and it did not change by the change in the pH of the dissolution medium. The tablets showed stability during a 6 months accelerated stability study according to appearance, drug content, disintegration time and dissolution profile. Thus it can be concluded that combining self emulsifying drug delivery technique and liquisolid technology can be a promising tool to enhance the dissolution profile of leflunomide in vitro. | en_US |
| dc.description.sponsorship | Elsevier | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=21100853576&tip=sid&clean=0 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.ispartofseries | Bulletin of Faculty of Pharmacy, Cairo University;Volume 55, Issue 1, June 2017, Pages 53-62 | |
| dc.subject | University of Liquisolid | en_US |
| dc.subject | Dissolution Enhancement | en_US |
| dc.title | Dissolution enhancement of leflunomide incorporating self emulsifying drug delivery systems and liquisolid concepts | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/10.1016/j.bfopcu.2017.02.001 | |
| dc.Affiliation | October University for modern sciences and Arts (MSA) |
